Combined oral anticoagulant and antiplatelet therapy is associated with a worse prognosis than anticoagulation alone in newly diagnosed atrial fibrillation patients without a clear indication for ...

In patients with cervical dissection, there was no difference in rates of stroke, residual stenosis, or occlusion at 1 year in those treated with anticoagulants and those treated with antiplatelet ...

Further results from the MASTER DAPT trial of abbreviated dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients at high bleeding risk stratified by use of oral ...

Munich, Germany - 28 Aug 2018: Combined oral anticoagulant and antiplatelet therapy is associated with a worse prognosis than anticoagulation alone in newly diagnosed atrial fibrillation patients ...

A new study suggests that a novel anti-clotting drug may reduce the risk of a second stroke without increasing bleeding, ...

Please provide your email address to receive an email when new articles are posted on . Clinical benefits of direct oral anticoagulants in addition to antiplatelet therapy as a secondary prevention ...

Patients with atrial fibrillation who took oral anticoagulants alone after undergoing transcatheter aortic valve replacement (TAVR) had a lower rate of bleeding complications without an increased risk ...

Patients with newly diagnosed atrial fibrillation who take not only an oral anticoagulant (OAC) but also an antiplatelet face increased risks of stroke and bleeding at 1 year, according to an analysis ...

Please provide your email address to receive an email when new articles are posted on . The multitarget stool DNA test had a positive predictive value of 31.4% for detecting advanced adenomas.

For patients with atrial fibrillation who undergo TAVR, being discharged on antiplatelet therapy seems key in reducing the risk of stroke at 2 years, according to post hoc analysis of PARTNER II data.

Ischemic adverse events, such as loss of vision and, less frequently, strokes, are the hallmarks of giant cell arteritis (GCA). Antiplatelet and anticoagulant therapy is thought to reduce the risk of ...

Despite favourable results in pivotal clinical trials involving novel direct oral anticoagulants, vitamin K antagonists remain the most commonly prescribed anticoagulant. Newer oral anticoagulants are ...